WellDoc BlueStar

The new clearance expands its insulin dosing support to bolus and premixed insulin titration for Type 2 diabetes.

Healthcare providers use a web interface to prescribe an initial dose "and BlueStar does the rest," according to Welldoc's chief medical officer.

Also: Consumer survey suggests declining digital health engagement; Iran's COVID-19 app pulled from Play Store after malware accusations.

WellDoc has expanded its BlueStar digital diabetes management platform to include a weight loss feature and a feature for those with both diabetes and hypertension.

Correction: A previous version of this story mistated the projected timeline for the combined product.

An analysis contracted by WellDoc found that the company’s digital therapeutic for Type 2 diabetes management could lead to an average savings of more than $250 per patient per month.

WellDoc announced today a partnership with the American Association of Diabetes Educators (AADE), a professional membership organization of over 14,000 diabetes educators.

Two of the biggest medical journals in the world have taken up some big picture mobile health questions this week: How are patients to know which medical apps work out of the sea of available options, and should healthy patients be making use of mobile health apps and devices at all? The first question is the subject of a recent article in the Journal of the American Medical Association, while the second is tackled in a point-counterpoint discussion in the British Medical Journal.